Valley National Advisers Inc. Lowers Stock Holdings in Pfizer Inc. $PFE

Valley National Advisers Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 16.6% in the 2nd quarter, Holdings Channel.com reports. The fund owned 9,208 shares of the biopharmaceutical company’s stock after selling 1,835 shares during the period. Valley National Advisers Inc.’s holdings in Pfizer were worth $223,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter valued at $27,000. North Capital Inc. bought a new stake in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd purchased a new position in Pfizer during the first quarter worth about $28,000. Horizon Financial Services LLC bought a new position in Pfizer in the 1st quarter worth about $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer in the 1st quarter valued at about $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 3.4%

Shares of PFE opened at $26.45 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The firm has a market cap of $150.38 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.88 and a beta of 0.55. The firm has a 50 day moving average price of $24.72 and a 200-day moving average price of $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.